Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Placebo-Controlled, Randomized, Double-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of AdimrSC-2f Vaccine in Healthy Adults

NCT05104489 is registered in ClinicalTrials.gov with Adimmune Corporation as lead sponsor.

NCT NCT05104489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05104489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Placebo-Controlled, Randomized, Double-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of AdimrSC-2f Vaccine in Healthy Adults
Lead sponsor
Adimmune Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
January 3, 2022
Completion date
July 26, 2023
Enrollment
241 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19